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During the last decennium, follow-up of cancer patients has been a
major topic in oncology research. In melanoma, the need and
benefit of follow-up has been discussed for many years and for
several reasons. The incidence of melanoma is increasing, but
without any increase in the mortality rate (Bataille and Vries,
2008). Consequently, the prevalence of melanoma is rising, with
more melanoma patients in follow-up. Melanoma patients are
reasonably young, and those who do not suffer from metastatic
disease are often in a remarkably good condition because the
initial melanoma treatment does not often dramatically impair
patients’ physical functioning. Furthermore, the risk of recurrence
is generally small (About 66% of melanoma cases at primary
diagnosis are stage 1a or 1b and have a 10-year survival rate of
more than 90 and 80%, respectively.) (Balch et al, 2009) and lastly,
currently no definite therapeutic options are known once the
metastatic disease presents.
The goal of melanoma follow-up is early detection of ‘curable’
disease, local recurrences, intransit metastases or nodal disease. Is
an intensive melanoma follow-up schedule justified to reach this
goal? Additional questions are (1) What do patients need in terms
of follow-up?; (2) What kind of follow-up is sensible and can be
offered?
Looking at the available literature, several aspects are of
importance. No international consensus exists on how melanoma
patients should be followed up after primary diagnosis, nor on the
frequency of clinical visits, on the duration of follow-up or on
which type of health-care professional to be consulted (Francken
et al, 2005). There seems to be consensus only on omitting routine
tests in follow-up, although some argue even on this aspect (Garbe
et al, 2003; Nieweg and Kroon, 2006).
Follow-up is appreciated by patients (Francken et al, 2007).
However, follow-up does not seem to have a role in the detection of
recurrences. Many patients detect recurrences and second primary
melanoma themselves (Francken et al, 2007, 2008). Self-examina-
tion seems to work well for many patients, but could be improved
for optimal benefit (Boone et al, 2009). Upcoming therapies to
treat patients with a recurrence effectively might change the
follow-up concepts for melanoma patients in the near future.
However, such therapies are currently available only in clinical
trials (Seetharamu et al, 2009).
The article of Murchie et al (2010) presents a prospective
randomised controlled trial on the feasibility of GP-led follow-up.
Patients were randomised between a follow-up programme with
their (recently trained) GP (intervention arm) and traditional
follow-up at the hospital melanoma clinic at Aberdeen Royal
Infirmary (control arm). Measurements were taken at baseline and
follow-up done by considering patient satisfaction as the primary
outcome and guideline adherence, quality of life, and anxiety and
depression as secondary outcomes. They found higher patient
satisfaction on several aspects of care received and better guideline
adherence at follow-up in the intervention group than in the
traditional hospital group, but not in quality of life or anxiety and
depression. Consequently, their careful conclusion is that GP-led
follow-up is feasible.
Several explanations can be given for the differences in
satisfaction found between the groups. Although Murchie et al
corrected for several biases (e.g., travel time to follow-up
appointment), not all bias could be eliminated. Patients in the
intervention group received a thorough skin examination by their
GP and, in addition, were given an information booklet on how to
conduct self-examination. This was not provided to the control
group. For the purpose of the study, GPs had recently received a
half-day training on how to examine and identify possible
(recurrent) melanomas. Moreover, GPs in the intervention group
had only a few melanoma patients to look after as compared with
the hospital physicians. Which ingredient would have worked?
Participation in the study, the recent training that the GPs had
received, the information booklet on self-examination or the small
number of patients that these GPs gave particular attention to? A
longer study follow-up is needed to gain insight into patient
satisfaction with GP follow-up once the melanoma follow-up is as
routine as in the hospital. Satisfaction from the GPs may also
change in the longer follow-up, because of increase in work
pressure (Bakker et al, 2002).
Heterogeneity in this study was high. Patients with all types of
melanoma p4mm Breslow thickness, as well as those with a time
since primary diagnosis of 6 months up to 10 years, were eligible.
These patients have a different prognosis and might have different
levels of disease performance. Although the patients were
randomised, heterogeneity might have influenced the outcome of
the study.
The most important question is about safety for patients
regarding morbidity, the detection of recurrences and mortality.
This aspect could not be studied because thousands of patients
would be needed, as explained by Murchie et al. We suspect
that this would not be affected by GP follow-up because self-
examination might anyway be the key to early detection. *Correspondence: Dr AB Francken; E-mail: abfrancken@hotmail.com
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can be performed by GPs without affecting patient satisfaction.
Follow-up of melanoma patients should be performed by well-
informed/educated and dedicated people. Patients should get
clear information on self-examination and their knowledge and
performance should be regularly examined. Future research should
focus on the contribution of providing this information to self-
examination and the true effect on morbidity and mortality. Future
studies may investigate the effect of regular examination of the
skin by a nurse practitioner or by even the patients’ partner or
significant other who has received a training comparable to the
one the GPs had.
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